Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 334 participants.

Also called NCT02177786

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 334 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02177786
Other papers using this trial's data
  • Effects of Selonsertib in Patients with Diabetic Kidney Disease Journal of the American Society of Nephrology : JASN, 2019-10 DOI, PubMed 31506292, PMC6779369 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02177786. Randomized; double masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-07 (actual). Results posted on 2019-06-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Intervention (Drug)
Selonsertib
Intervention (Drug)
Placebo to match selonsertib
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct02177786
Content hash
622f887718ac08b54b12ad078e49efc72bef9209e3aaaddb548c1cd995378b87